DONEPEZIL HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H29NO3.ClH
Molecular Weight	415.953
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.COC1=CC2=C(C=C1OC)C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)C2

InChI

InChIKey=XWAIAVWHZJNZQQ-UHFFFAOYSA-N

InChI=1S/C24H29NO3.ClH/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18;/h3-7,14-15,17,20H,8-13,16H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C24H29NO3
Molecular Weight	379.492
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020690s035,021720s008,022568s005lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9428950

Donepezil, marketed under the trade name Aricept, is a medication used in the palliative treatment of Alzheimer's disease. Aricept is indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild to moderate Alzheimer’s Disease, as well as in patients with severe Alzheimer’s Disease. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. Donepezil has been tested in other cognitive disorders including Lewy body dementia and Vascular dementia, but it is not currently approved for these indications. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Acetylcholinesterase 207 Target ID: CHEMBL220 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020690s035,021720s008,022568s005lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/11256231 \| https://www.ncbi.nlm.nih.gov/pubmed/16570913	Inhibitor 8228		6.7 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 268 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020690s035,021720s008,022568s005lbl.pdf	Palliative		Approved 8360	ARICEPT Approved Use Donepezil hydrochloride orally disintegrating tablets, USP are an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's Disease (1). Donepezil hydrochloride orally disintegrating tablets, USP are indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease. Launch Date 8.4888001E11

C_max

Value	Dose	Co-administered	Analyte	Population
34.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DONEPEZIL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
60.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DONEPEZIL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
2889.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DONEPEZIL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5051.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DONEPEZIL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
72.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DONEPEZIL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
73.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DONEPEZIL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
4.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DONEPEZIL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DONEPEZIL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
175 mg single, transdermal Dose: 175 mg Route: transdermal Route: single Dose: 175 mg Sources: https://pubmed.ncbi.nlm.nih.gov/32440098	healthy, 24.9±3.3 years n = 9 Health Status: healthy Age Group: 24.9±3.3 years Sex: M Population Size: 9 Sources: https://pubmed.ncbi.nlm.nih.gov/32440098	Sources: https://pubmed.ncbi.nlm.nih.gov/32440098
175 mg 1 times / 3 days steady, transdermal Dose: 175 mg, 1 times / 3 days Route: transdermal Route: steady Dose: 175 mg, 1 times / 3 days Sources: https://pubmed.ncbi.nlm.nih.gov/32440098	healthy, 24.9±3.3 years n = 9 Health Status: healthy Age Group: 24.9±3.3 years Sex: M Population Size: 9 Sources: https://pubmed.ncbi.nlm.nih.gov/32440098	Sources: https://pubmed.ncbi.nlm.nih.gov/32440098
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf Page: p. 50	unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf Page: p. 50	Disc. AE: Bradycardia, Diarrhea... AEs leading to discontinuation/dose reduction: Bradycardia (0.7%) Diarrhea (1.7%) Nausea (1.9%) Vomiting (2.9%) QT interval prolonged (0.4%) Anorexia (0.3%) Dizziness (1.1%) Headache (0.4%) Somnolence (0.6%) Syncope (0.2%) Aggression (0.5%) Agitation (0.8%) Confusional state (0.7%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf Page: p. 50
50 mg single, oral Overdose Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/10466911	unhealthy, 79 years n = 1 Health Status: unhealthy Condition: Alzheimer disease Age Group: 79 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10466911	Other AEs: Nausea, Vomiting... Other AEs: Nausea (1 patient) Vomiting (1 patient) Bradycardia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/10466911
30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25202036	unhealthy, 80 years n = 1 Health Status: unhealthy Condition: Alzheimer disease Age Group: 80 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25202036	Disc. AE: Myoclonus... AEs leading to discontinuation/dose reduction: Myoclonus (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/25202036
10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf	unhealthy, adult n = 315 Health Status: unhealthy Age Group: adult Population Size: 315 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf	Other AEs: Diarrhea, Nausea... Other AEs: Diarrhea (3%) Nausea (3%) Vomiting (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf	unhealthy, adult n = 350 Health Status: unhealthy Age Group: adult Population Size: 350 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (<1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf

AEs

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:53289	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:53289
ChemicalBook	CB0156314	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0156314
ChemicalBook	CB23334700	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB23334700
ChemicalBook	CB62741796	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB62741796
ChemicalBook	CB73050236	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB73050236
MolPort	MolPort-003-847-014	https://www.molport.com/shop/molecule-link/MolPort-003-847-014
eMolecules	873089	https://www.emolecules.com/cgi-bin/more?vid=873089

PubMed

Title	Date	PubMed
Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?	2001	11888344
EEG changes during long-term treatment with donepezil in Alzheimer's disease patients.	2001	11725819
Pharmacokinetic rationale for switching from donepezil to galantamine.	2001	11396871
Switching previous therapies for Alzheimer's disease to galantamine.	2001	11396869
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates.	2001	11320158
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.	2001	11262420
Cerebral blood flow and metabolic abnormalities in Alzheimer's disease.	2001 Apr	11448080
Muscarinic agonists and antagonists in the treatment of Alzheimer's disease.	2001 Apr	11421251
Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder.	2001 Apr	11336608
Determination of inhibitors' potency (IC50) by a direct high-performance liquid chromatographic method on an immobilised acetylcholinesterase column.	2001 Apr 5	11334353
Maintaining functional and behavioral abilities in Alzheimer disease.	2001 Aug	11669508
Maintaining cognitive function in Alzheimer disease: how effective are current treatments?	2001 Aug	11669506
Motor cortex disinhibition in Alzheimer's disease.	2001 Aug	11459683
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.	2001 Aug 14	11502917
Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy.	2001 Aug 14	11502915
Donepezil in schizophrenia--is it helpful? An experimental design case study.	2001 Dec	11782241
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].	2001 Dec 13	11824165
Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons.	2001 Feb	11226748
[Early recognition not hopeless. Alzheimer disease can be delayed].	2001 Feb 8	11247376
Donepezil for Down's syndrome.	2001 Jan	11136652
Use of cholinesterase inhibitors for treatment of Alzheimer disease.	2001 Jul	11453078
Open-label study of donepezil in traumatic brain injury.	2001 Jul	11441374
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients.	2001 Jul-Sep	11522934
Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation.	2001 Jun 22	11403956
Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.	2001 Mar	11255448
Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.	2001 Mar	11255446
Analysis and enantioresolution of donepezil by capillary electrophoresis.	2001 Mar	11248479
Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target.	2001 Nov	11589917
SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals.	2001 Nov 16	11728425
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].	2001 Nov 29	11789125
Synthesis and screening for antiacetylcholinesterase activity of (1-benzyl-4-oxopiperidin-3-ylidene)methylindoles and -pyrroles related to donepezil.	2001 Nov 8	11689088
Treatment of tardive dyskinesia with donepezil: a pilot study.	2001 Oct	11816865
Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles.	2001 Winter	11830754
Economic evaluation of donepezil treatment for Alzheimer's disease in Japan.	2002	11731713
Feasibility of vascular dementia treatment with cholinesterase inhibitors.	2002 Feb	11813286
[Pharmacotherapy for the treatment of Alzheimer's disease--the present state and the development in the future].	2002 Jan	11808319
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.	2002 Mar	11921156
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.	2002 Mar 12	11889261
Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection.	2002 Mar 5	11888054

Patents

Sample Use Guides

In Vivo Use Guide

Mild to Moderate Alzheimer’s Disease - 5 mg or 10 mg administered once daily Moderate to Severe Alzheim er’s Disease - 10 mg or 23 mg administered once daily A dose of 10 mg once daily can be administered once patients have been on a daily dose of 5 mg for 4 to 6 weeks. A dose of 23 mg once daily can be administered once patien ts have been on a dose of 10 mg once daily for at least 3 months

Route of Administration: Oral

In Vitro Use Guide

Donepezil inhibited freshly prepared human erythrocyte AChE with IC50 22 nM

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:00:59 UTC 2023` Edited by `admin` on `Wed Jul 05 23:00:59 UTC 2023`
Record UNII	3O2T2PJ89D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DONEPEZIL HYDROCHLORIDE

Official Name

English

BNAG

Common Name

English

NAMZARIC COMPONENT DONEPEZIL HYDROCHLORIDE

Brand Name

English

Donepezil hydrochloride [WHO-DD]

Common Name

English

(±)-2-((1-BENZYL-4-PIPERIDYL)METHYL)-5,6-DIMETHOXY-1-INDANONE HYDROCHLORIDE

Systematic Name

English

DONEPEZIL HYDROCHLORIDE [JAN]

Common Name

English

DONEPEZIL HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

NSC-737535

Code

English

DONEPEZIL HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

DONEPEZIL HYDROCHLORIDE [USP-RS]

Common Name

English

DONEPEZIL HYDROCHLORIDE [MART.]

Common Name

English

E2020

Code

English

DONEPEZIL HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

E-2020

Code

English

NSC-758882

Code

English

DONEPEZIL HYDROCHLORIDE COMPONENT OF NAMZARIC

Brand Name

English

DONEPEZIL HCL

Common Name

English

DONEPEZIL HYDROCHLORIDE [MI]

Common Name

English

DONEPEZIL HYDROCHLORIDE [VANDF]

Common Name

English

ARICEPT

Brand Name

English

DONEPEZIL HYDROCHLORIDE [USAN]

Common Name

English

ADLARITY

Brand Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

BALAXUR (REFUSED: ALZHEIMER DISEASE)